Lou Jiatao, Zhang LingFei, Lv Shaogang, Zhang Chenzi, Jiang Shuai
Department of Laboratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Center for RNA Research, State Key Laboratory of Molecular Biology, Chinese Academy of Sciences (CAS), Shanghai, China.
Biomark Cancer. 2017 Feb 28;9:1-9. doi: 10.1177/1179299X16684640. eCollection 2017.
Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide. The HCC diagnosis is usually achieved by biomarkers, which can also help in prognosis prediction. Furthermore, it might represent certain therapeutic interventions through some combinations of biomarkers. Here, we review on our current understanding of HCC biomarkers.
肝细胞癌（HCC）是全球癌症死亡的第三大主要原因。HCC的诊断通常通过生物标志物来实现，这些生物标志物也有助于预后预测。此外，通过某些生物标志物的组合，它可能代表特定的治疗干预措施。在此，我们综述了目前对HCC生物标志物的认识。
